In an effort to increase the diagnostic rate and improve the outcome for myeloma patients in China, we established a diagnostic approach driven by monoclonal immunoglobulins (M-protein) screening in our institute, Zhongshan Hospital Fudan University. The gene discussed is MYOM2; the disease is plasma cell myeloma.